StreetAlpha.app
Home › Stocks › LKFT

Lakefront Biotherapeutics NV (LKFT)

Healthcare
$34.39
▼ −1.15%
LAST CLOSE · NOV 17

Lakefront Biotherapeutics is a Belgian biotechnology company developing medicines for serious immune and inflammatory diseases. It last closed at $34.39 on Nov 17, down 1.15% on the day. The average 12-month price target from 2 analysts is $36.00 (+4.7% from the last close), with a high of $45.00 and a low of $27.00. In the past 30 days there were 1 dark pool print totaling $790K, the largest $790K.

AI Auto Pilots
Is LKFT in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
EUR 1.1B
+303.5% vs a year ago
Net income
EUR 320.9M
+333.1% vs a year ago
Free cash flow
−EUR 271.2M
−24.4% margin
Operating margin
26.5%
EUR 295.0M operating income
Balance sheet
Cash & equivalents
EUR 87.9M
At Dec 31
Shareholder equity
EUR 3.2B
ExchangeNasdaq
Financials history
FY2021: EUR 234.4MEUR 234.4MFY2021FY2022: EUR 241.2MEUR 241.2MFY2022FY2023: EUR 239.7MEUR 239.7MFY2023FY2024: EUR 275.6MEUR 275.6MFY2024FY2025: EUR 1.1BEUR 1.1BFY2025

From LKFT's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 26). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated LKFT in the past 90 days, not enough for a consensus
Average 12-month target
$36.00
▲ 4.7% upside

Based on 2 analysts who set a price target on LKFT in the past 90 days. The average target is $36.00, with a high of $45.00 and a low of $27.00, compared with the last close of $34.39.

Low $27.00Avg $36.00High $45.00
Blue marker: last close $34.39
Highest target$45.00
Average target$36.00
Lowest target$27.00
Latest rating changes
Morgan StanleyTarget raised
Nov 16Hold$26 → $27
RBC CapitalUpgrade
Sep 23Buy$26 → $45
Morgan StanleyMaintained
Aug 11Hold$26
RBC CapitalMaintained
Aug 11Hold$26
DateFirmActionRatingPrice target
Nov 16Morgan StanleyTarget raisedHold$26 → $27
Sep 23RBC CapitalUpgradeBuy$26 → $45
Aug 11Morgan StanleyMaintainedHold$26
Aug 11RBC CapitalMaintainedHold$26
Loading…

Technical Analysis

LKFT · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 5% above its 20 day and 11% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 70), overbought. The nearest support is the Pivot S1 at $34.12, and the nearest resistance the swing high (Nov 5) at $34.49.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 2.7%/day
Key levels
$36.2452 week high+5.4%
$34.91Pivot R1+1.5%
$34.64Pivot+0.7%
$34.49Swing high (Nov 5)+0.3%
$34.39Last close
$34.12Pivot S1−0.8%
$32.8220 day average−4.6%
$30.6250 day average−11.0%
$29.89200 day average−13.1%
$29.64100 day average−13.8%
$28.71Swing low (Oct 1)−16.5%
$25.6852 week low−25.3%
Indicators
RSI (14)70.11Overbought above 70Overbought
MACD1.09Above its signal lineBullish
Stochastic71.1Middle of its rangeNeutral
ADX (14)29.6Trending up
Williams %R-31.6Oversold below −80, overbought above −20Neutral
CCI (20)118.1Oversold below −100, overbought above 100Overbought
Rate of change+7.0%Change over 10 sessionsBullish
ATR (14)$0.92Typical daily range, 2.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for LKFT

What happened before

See how LKFT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LKFT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LKFT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LKFT in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$790K
Largest print
$790K
Loading…

LKFT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 30 selling
  • ▲Shares held by funds +4.7%
  • ▲Funds holding +16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9579+20.3%
In funds' top 1045−20.0%
Held by funds–––
New / increased22 / 3511 / 26+54.1%
Reduced / sold out23 / 728 / 21−38.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LKFT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LKFT is in one of them and how their past LKFT trades turned out.

LKFT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LKFT in an article yet. Here's the latest on the wider market.

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics is a biotechnology company based in Mechelen, Belgium, that develops medicines for patients with serious diseases. Its main focus is immunology, where its lead candidate is an oral medicine being studied in lupus and dermatomyositis, two autoimmune conditions. The company has also decided to wind down its cell therapy work in cancer and is seeking new business development deals to advance its remaining drug candidates.

Headquarters
2800 Mechelen
Founded
1999